Core Viewpoint - Wells Fargo has raised its price target for Merck (MRK) to $150, driven by the potential of sacituzumab tirumotecan (sac-TMT) to replace chemotherapy in various cancer treatments, alongside the growth of KEYTRUDA and a robust pipeline of 80 Phase 3 studies [1] Group 1: Stock Performance and Predictions - Merck's stock has gained 23% over the past year and 8% year-to-date, currently trading below its 52-week high of $125.14 [1] - The Street consensus price target for Merck is $127.22, while Wells Fargo's target of $150 suggests significant upside potential [1] - Achieving a $150 price target would imply a market capitalization exceeding $283.4 billion, necessitating positive late-stage data for sac-TMT and sustained growth for KEYTRUDA [1] Group 2: Key Drivers of Stock Performance - Emerging growth portfolio: WINREVAIR, Merck's treatment for pulmonary arterial hypertension, generated $467 million in Q4 2025, reflecting a 133% year-over-year increase [1] - KEYTRUDA's revenue reached $8.337 billion in Q4 2025, up 6% year-over-year, with new FDA approvals expanding its indications [1] - The potential of sac-TMT to displace chemotherapy in multiple cancer types represents a significant commercial opportunity for Merck's oncology franchise [1] Group 3: Strategic Developments - The FDA awarded sac-TMT a Commissioner's National Priority Voucher, indicating strong regulatory support for its development [1] - A strategic financing agreement with Blackstone Life Sciences has been established to partially fund the development of sac-TMT [1]